Two new studies consider the potential of using psychedelics to help treat depression. Imperial College London researchers report psilocybin, the active compound in magic mushrooms, can help to relieve symptoms of depression without the dulling of emotions associated with SSRIs. The researchers note the psychedelic experience could help to maintain long term mental health for those with treatment resistant depression.
Cannabidiol treatment helped reduce anxiety severity by, on average, 42.6% in young adults with treatment-resistant anxiety, a new study reports.
A study using rat models of depression reveals a single dose of the cannabis extract CBD can help to reduce symptoms of depression for up to one week. Researchers say cannabidiol appears to activate mechanisms that help repair neural circuitry in the prefrontal cortex and hippocampus, which get damaged as a result of depression.
Female rats exposed to vaporized cannabis for 30 days developed a blunted response to stress. The effect was not seen in male rats. Findings shed light on how chronic cannabis use affects males and females differently.
According to researchers, regular use of the popular clubbing drug, GBH, can have negative effects on brain networks associated with both long term and working memory. Additionally, frequent use of the drug is associated with an increased risk of developing stress and anxiety.
A new study reports combining antipsychotic medications could help to prevent relapse and hospitalization for those with schizophrenia. Combining aripiprazole and clozapine resulted in a 23% lower risk of re-hospitalization than with clozapine alone, researchers report.
Sertraline (Zoloft), a commonly prescribed SSRI antidepressant, may not be as effective at treating depression within 6 weeks as previously thought. However, the drug is effective for treating anxiety symptoms.